Skip to content
We’ve expanded our free plan so you can explore more of Valuesider. Check out the updated pricing page to see what’s now available for free!
User

Egerton Capital MDLN trades

John Armitage

John Armitage Medline Inc, CL-A stake

total: 222

Trades details

Total transactions:
2
New positions:
1
Added:
1
Held since:
2026 Q1
Held for:
2 quarters
Latest activity:
2026 Q2
According to 2026 Q2 report, John Armitage holds 16,470,884 Medline Inc, CL-A (MDLN) shares with a market value of roughly $649.61M accounting for 6.28% of the overall portfolio. To date, the estimated cost basis is nearly $40.78 for "buy" trades. Egerton Capital first purchased MDLN in 2026 Q1, initially acquiring about 4.37M shares. Since the initial investment in Medline Inc, CL-A (MDLN), Egerton Capital has made 1 more transaction.

How many MDLN shares does John Armitage currently hold?

According to 2026 Q2 report, John Armitage holds 16,470,884 shares of Medline Inc, CL-A (MDLN), valued at around $649.61M.

When did John Armitage buy Medline Inc, CL-A (MDLN)?

John Armitage first invested in Medline Inc, CL-A (MDLN) in 2026 Q1 at the reported quarter-end price of $44.50 per share.

What's the cost basis of Egerton Capital's MDLN stake?

The estimated cost basis for Medline Inc, CL-A (MDLN) stake is around $40.78 per share. This represents their average reported price* across all buy transactions

Estimated cost basis*

Weighted AVG buy price:
$40.78

John Armitage's historical trades in Medline Inc, CL-A

2 results
Period % of
portfolio
Shares
held after*
Reported
price*
Value* % (shares)
of activity
% change
to portfolio
2026 Q2
6.28%
16,470,884
$39.44
$649,611,665
+277.27% (+12,105,082)
+4.61%
2026 Q1
2.16%
4,365,802
$44.50
$194,278,189
new
+2.16%
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.